HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New York’s Age Restrictions On Weight Loss, Sports Supplement Sales Fail To Fly

Banning Sales To Minors Still Could Have Wings To Pass There, Other States

Executive Summary

New York legislation to restrict sales of weight loss and sports nutrition supplements to minors failed without reaching a vote before the end of the session. But the proposal will continue to be a challenge for industry in New York as well as around the country.

You may also be interested in...



States’ Proposals To Age-Restrict Sports Nutrition Sales Miss Targeted Problems But Hit Retailers

MA and NY lawmakers propose prohibiting sales to consumers under 18 of supplements, OTC drugs for weight loss and muscle building and imposing $2,000 fines for violations. Supplement industry trade groups say the laws would not help solve eating disorders but would hammer retailers.

Final Quarter Of P&G CEO Taylor’s Tenure Could Become Stormy With Headwinds From Rising Costs

P&G’s health care sector’s net sales grew 18% in its latest quarter. Continued growth across its sectors is critical in the face of expected $1.8bn in headwinds from commodity and freight costs in its FY2022.

Restoring FTC Monetary Relief Authority: For Commission Members, Not One Size Fits All

House already passed legislation to amend Sec. 13(b) of FTC regulations and make explicit its authority to obtain injunctive and equitable relief in court, but differences in Democrat and Republican commission appointees' views on the authority was a key topic of discussion during a recent Energy and Commerce hearing.

Topics

UsernamePublicRestriction

Register

RS151429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel